Molecular imaging of autoimmune diseases and inflammation

Molecular Imaging

Volumn 11, Issue 3, 2012, Pages 251-264

  Anna Sargsyan, S ^a   Thurman, Joshua M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; CLINICAL ASSESSMENTS; DISEASE BIOMARKER; GOLD STANDARDS; IMMUNE ACTIVATION; INFLAMMATORY ACTIVITY; INFLAMMATORY DISEASE; MOLECULAR SIGNATURES; NON-INVASIVE DETECTION; PHARMACOLOGIC AGENTS; TARGET TISSUES; TISSUE BIOPSIES; TISSUE INFLAMMATION;

HISTOLOGY; MOLECULES; PATHOLOGY; TISSUE;

MOLECULAR IMAGING;

ARTICLE; AUTOIMMUNE DISEASE; HUMAN; INFLAMMATION; MOLECULAR IMAGING;

AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; MOLECULAR IMAGING;

EID: 84862704864     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00045     Document Type: Article

References (129)

1. Bruce IN. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:273-7, doi:10. 1097/BOR. 0b013e3283374e78.
2. Dighe AS, Richards E, Old LJ, et al. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56, doi:10. 1016/1074-7613 (94) 90087-6.
3. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61, doi:10.1038/nri2294. (Pubitemid 351595216)
4. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009;30:899-911, doi:10. 1016/j.immuni.2009.03. 019.
5. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97:133-44, doi:10.1016/S0092-8674 (00) 80721-7. (Pubitemid 29165896)
6. Kastner DL, Aksentijevich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010;140:784-90, doi:10.1016/j.cell.2010. 03.002.
7. *'). Annu Rev Immunol 2009;27:621-68, doi:10.1146/annurev. immunol.25.022106.141627.
8. Fleming SD, Shea-Donohue T, Guthridge JM, et al. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 2002;169:2126-33. (Pubitemid 34857679)
9. Zhang M, Austen WG Jr, Chiu I, et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2004;101:3886-91, doi:10.1073/pnas.0400347101. (Pubitemid 38381072)
10. Carroll MC, Holers VM. Innate autoimmunity. Adv Immunol 2005;86:137-57, doi:10.1016/S0065-2776 (04) 86004-8. (Pubitemid 40215692)
11. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 2008;58(2 Suppl):S92-S101, doi:10.1002/art.23362.
12. Peyrin-Biroulet L, Deltenre P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53, doi:10.1016/j.cgh.2008.03.014. (Pubitemid 351783447)
13. Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42:617-21, doi:10.1093/rheumatology/keg263. (Pubitemid 37220869)
14. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (rmetHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial Arthritis Rheum 2003;48:927-34.
15. Mok CC. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010;2010:638413.
16. Ley K, Laudanna C, Cybulsky MI, et al. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007;7:678-89, doi:10.1038/nri2156. (Pubitemid 47327397)
17. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054-9.
18. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int 1973;3:74-89, doi:10.1038/ki.1973.14.
19. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50, doi:10.1097/01. ASN.000010 8969.21691.5D. (Pubitemid 38140764)
20. Pillemer SR, Austin HA 3rd, Tsokos GC, et al. Lupus nephritis: association between serology and renal biopsy measures. J Rheumatol 1988;15:284-8. (Pubitemid 18073753)
21. Signore A, Mather SJ, Piaggio G, et al. Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. Chem Rev 2010;110:3112-45, doi:10.1021/cr900351r.
22. Vargas ER, Chen JW. Magnetic resonance imaging agents. In: Molecular imaging: principles and practice. Shelton (CT): People's Medical Publishing House; 2010.
23. Madsen MT. Recent advances in SPECT imaging. J Nucl Med 2007;48:661-73, doi:10.2967/jnumed.106.032680. (Pubitemid 47571425)
24. Glaudemans AW, Slart RH, Bozzao A, et al. Molecular imaging in atherosclerosis. Eur J Nucl Med Mol Imaging 2010;37:2381-97, doi:10.1007/s00259-010-1406-4.
25. Mansfield JC, Giaffer MH, Tindale WB, et al. Quantitative assessment of overall inflammatory bowel disease activity using labelled leucocytes: a direct comparison between indium-111 and technetium-99m HMPAO methods. Gut 1995;37:679-83, doi:10.1136/gut.37.5.679.
26. Papathanasiou ND, Rondogianni PE, Pianou NK, et al. 99mTc depreotide in the evaluation of bone infection and inflammation. Nucl Med Commun 2008;29:239-46, doi:10.1097/MNM. 0b013e3282f20e30. (Pubitemid 351499300)
27. Lees AM, Lees RS, Schoen FJ, et al. Imaging human atherosclerosis with 99mTc-labeled low density lipoproteins. Arteriosclerosis 1988;8:461-70, doi:10.1161/01. ATV.8.5.461.
28. Wunder A, Klohs J, Dirnagl U. Non-invasive visualization of CNS inflammation with nuclear and optical imaging. Neuroscience 2009;158:1161-73, doi:10.1016/j.neuroscience.2008.10.005.
29. ten Berge RJ, Natarajan AT, Hardeman MR, et al. Labeling with indium-111 has detrimental effects on human lymphocytes: concise communication. J Nucl Med 1983;24:615-20. (Pubitemid 13049714)
30. Kinne RW, Emmrich F, Freesmeyer M. Clinical impact of radiolabeled anti-CD4 antibodies in the diagnosis of rheumatoid arthritis. Q J Nucl Med Mol Imaging 2010;54:629-38.
31. Kinne RW, Becker W, Schwab J, et al. Comparison of 99Tcm labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun 1993;14:667-75, doi:10.1097/00006231-199308000-00007. (Pubitemid 23233480)
32. Marcus C, Thakur ML, Huynh TV, et al. Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nucl Med Commun 1994;15:824-30, doi:10.1097/00006231-199410000-00008. (Pubitemid 24317026)
33. Chapman PT, Jamar F, Keelan ET, et al. Use of a radiolabeled monoclonal antibody against E-selectin for imaging of endothelial activation in rheumatoid arthritis. Arthritis Rheum 1996;39:1371-5, doi:10.1002/art.1780390815. (Pubitemid 26270097)
34. Jamar F, Houssiau FA, Devogelaer JP, et al. Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis. Rheumatology (Oxford) 2002;41:53-61, doi:10. 1093/rheumatology/41.1.53. (Pubitemid 34537921)
35. Conti F, Priori R, Chimenti MS, et al. Successful treatment with intraarticular infliximab for resistant knee monarthritis in a patient with spondylarthropathy: a role for scintigraphy with 99mTc-infliximab. Arthritis Rheum 2005;52:1224-6, doi:10.1002/art.20979. (Pubitemid 40530130)
36. Barrera P, Oyen WJ, Boerman OC, et al. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:825-8, doi:10.1136/ard.62.9.825. (Pubitemid 37026491)
37. Chianelli M, Mather SJ, Grossman A, et al. 99mTc-interleukin-2 scintigraphy in normal subjects and in patients with autoimmune thyroid diseases: a feasibility study. Eur J Nucl Med Mol Imaging 2008;35:2286-93, doi:10.1007/s00259-008-0837-7.
38. Signore A, Chianelli M, Annovazzi A, et al. 123I-Interleukin-2 scintigraphy for in vivo assessment of intestinal mononuclear cell infiltration in Crohn disease. J Nucl Med 2000;41:242-9. (Pubitemid 30091342)
39. Signore A, Chianelli M, Annovazzi A, et al. Imaging active lymphocytic infiltration in coeliac disease with iodine-123-interleukin-2 and the response to diet. Eur J Nucl Med 2000;27:18-24, doi:10.1007/PL00006657. (Pubitemid 30097255)
40. Signore A, Picarelli A, Annovazzi A, et al. 123I-Interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun 2003;24:305-16, doi:10.1097/00006231-200303000-00011.
41. Su H, Spinale FG, Dobrucki LW, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005;112:3157-67, doi:10.1161/CIRCULATIONAHA.105.583021.
42. De Winter F, Vogelaers D, Gemmel F, et al. Promising role of 18-F-fluoro-D-deoxyglucose positron emission tomography in clinical infectious diseases. Eur J Clin Microbiol Infect Dis 2002;21:247-57, doi:10.1007/s10096- 002-0708-2. (Pubitemid 34507868)
43. Laffon E, Barret O, Marthan R, et al. Is the physical decay correction of the (18) F-FDG input function in dynamic PET imaging justified? J Nucl Med Technol 2009;37:111-3, doi:10.2967/jnmt.108.060350.
44. Davies JR, Rudd JH, Weissberg PL. Molecular and metabolic imaging of atherosclerosis. J Nucl Med 2004;45:1898-907. (Pubitemid 47618449)
45. Beckers C, Ribbens C, Andre B, et al. Assessment of disease activity in rheumatoid arthritis with (18) F-FDG PET. J Nucl Med 2004;45:956-64. (Pubitemid 47611682)
46. Rini JN, Bhargava KK, Tronco GG, et al. PET with FDG-labeled leukocytes versus scintigraphy with 111In-oxine-labeled leukocytes for detection of infection. Radiology 2006;238:978-87, doi:10.1148/radiol.2382041993. (Pubitemid 43289930)
47. Banati RB, Goerres GW, Myers R, et al. [11C] (R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology 1999;53:2199-203.
48. Cagnin A, Myers R, Gunn RN, et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001;124:2014-27, doi:10.1093/brain/124.10.2014. (Pubitemid 32945901)
49. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123(Pt 11):2321-37, doi:10.1093/brain/123.11.2321.
50. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461-7, doi:10.1016/S0140-6736 (01) 05625-2. (Pubitemid 32769854)
51. Turner M, Cagnin A, Turkheimer F, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C] (R)-PK11195 positron emission tomography study. Neurobiol Dis 2004;15:601-9, doi:10.1016/j.nbd.2003.12.012. (Pubitemid 38429975)
52. Venneti S, Lopresti BJ, Wang G, et al. A comparison of the highaffinity peripheral benzodiazepine receptor ligands DAA1106 and (R)-PK11195 in rat models of neuroinflammation: implications for PET imaging of microglial activation. J Neurochem 2007;102:2118-31, doi:10.1111/j.1471-4159.2007.04690.x. (Pubitemid 47329281)
53. Van Camp N, Boisgard R, Kuhnast B, et al. In vivo imaging of neuroinflammation: a comparative study between [(18) F] PBR111, [(11) C]CLINME and [(11) C]PK11195 in an acute rodent model. Eur J Nucl Med Mol Imaging 2010;37:962-72, doi:10.1007/s00259-009-1353-0.
54. Wang H, Pullambhatla M, Guilarte TR, et al. Synthesis of [(125) I]iodoDPA-713: a new probe for imaging inflammation. Biochem Biophys Res Commun 2009;389:80-3, doi:10.1016/j.bbrc.2009.08.102.
55. Cao Q, Cai W, Li ZB, et al. PET imaging of acute and chronic inflammation in living mice. Eur J Nucl Med Mol Imaging 2007;34:1832-42, doi:10.1007/s00259-007-0451-0. (Pubitemid 47599047)
56. Laitinen I, Saraste A, Weidl E, et al. Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice. Circ Cardiovasc Imaging 2009;2:331-8, doi:10.1161/CIRCIMAGING.108.846865.
57. Ujula T, Salomaki S, Virsu P, et al. Synthesis, 68Ga labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1:a potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 2009;36:p. 631-41.
58. Nahrendorf M, Keliher E, Panizzi P, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging 2009;2:1213-22, doi:10.1016/j.jcmg.2009.04.016.
59. Nahrendorf M, Keliher E, Marinelli B, et al. Detection of macrophages in aortic aneurysms by nanoparticle positron emission tomography-computed tomography. Arterioscler Thromb Vasc Biol 2011;31:750-7, doi:10.1161/ATVBAHA. 110.221499.
60. Jarrett BR, Correa C, Ma KL, et al. In vivo mapping of vascular inflammation using multimodal imaging. PLoS One 2010;5:e13254, doi:10.1371/journal.pone.0013254.
61. Nahrendorf M, Zhang H, Hembrador S, et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 2008;117:379-87, doi:10.1161/CIRCULATIONAHA. 107.741181.
62. Silvola JM, Saraste A, Forsback S, et al. Detection of hypoxia by [18F]EF5 in atherosclerotic plaques in mice. Arterioscler Thromb Vasc Biol 2011;31:1011-5, doi:10.1161/ATVBAHA.110.221440.
63. Glaudemans AW, Signore A. FDG-PET/CT in infections: the imaging method of choice? Eur J Nucl Med Mol Imaging 2010;37:1986-91, doi:10.1007/s00259-010- 1587-x.
64. Glaudemans AW, Maccioni F, Mansi L, et al. Imaging of cell trafficking in Crohn disease. J Cell Physiol 2010;223:562-71.
65. Tahara N, Kai H, Ishibashi M, et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31, doi:10. 1016/j.jacc.2006.03.069. (Pubitemid 44648621)
66. Henes JC, Muller M, Krieger J, et al. [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. Clin Exp Rheumatol 2008;26(3 Suppl 49):S47-52.
67. Meller J, Sahlmann CO, Scheel AK. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 2007;48:35-45. (Pubitemid 47555372)
68. Gotthardt M, Bleeker-Rovers CP, Boerman OC, et al. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med 2010;51:1937-49, doi:10.2967/jnumed.110.076232.
69. Voigt JU. Ultrasound molecular imaging. Methods 2009;48:92-7, doi:10.1016/j.ymeth.2009.03.011.
70. Quaia E. Microbubble ultrasound contrast agents: an update. Eur Radiol 2007;17:1995-2008, doi:10.1007/s00330-007-0623-0. (Pubitemid 47097457)
71. Hauff P, Reinhardt M, Briel A, et al. Molecular targeting of lymph nodes with L-selectin ligand-specific US contrast agent: a feasibility study in mice and dogs. Radiology 2004;231:667-73, doi:10.1148/radiol.2313030425. (Pubitemid 38668081)
72. Christiansen JP, Leong-Poi H, Klibanov AL, et al. Noninvasive imaging of myocardial reperfusion injury using leukocytetargeted contrast echocardiography. Circulation 2002;105:1764-7, doi:10.1161/01. CIR.0000015466.89771. E2. (Pubitemid 34408882)
73. Lindner JR, Ismail S, Spotnitz WD, et al. Albumin microbubble persistence during myocardial contrast echocardiography is associated with microvascular endothelial glycocalyx damage. Circulation 1998;98:2187-94. (Pubitemid 28527479)
74. Lindner JR, Coggins MP, Kaul S, et al. Microbubble persistence in the microcirculation during ischemia/reperfusion and inflammation is caused by integrin-and complement-mediated adherence to activated leukocytes. Circulation 2000;101:668-75. (Pubitemid 30094739)
75. Weller GE, Lu E, Csikari MM, et al. Ultrasound imaging of acute cardiac transplant rejection with microbubbles targeted to intercellular adhesion molecule-1. Circulation 2003;108:218-24, doi:10.1161/01. CIR.0000080287.74762. 60. (Pubitemid 36871306)
76. Bachmann C, Klibanov AL, Olson TS, et al. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn disease. Gastroenterology 2006;130:8-16, doi:10.1053/j.gastro.2005.11.009. (Pubitemid 43049830)
77. Weller GE, Villanueva FS, Tom EM, et al. Targeted ultrasound contrast agents: in vitro assessment of endothelial dysfunction and multi-targeting to ICAM-1 and sialyl Lewisx. Biotechnol Bioeng 2005;92:780-8, doi:10.1002/bit. 20625. (Pubitemid 41772473)
78. Butalia S, Palda VA, Sargeant RJ, et al. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 2008;299:806-13, doi:10.1001/jama.299.7.806. (Pubitemid 351281574)
79. Serkova N, Renner B, Larsen B, et al. Renal inflammation: targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology 2010;255:517-26, doi:10.1148/radiol.09091134.
80. Gaglia JL, Guimaraes AR, Harisinghani M, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest 2011;121:442-5, doi:10.1172/JCI44339.
81. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-93. (Pubitemid 20135290)
82. Ruehm SG, Corot C, Vogt P, et al. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 2001;103:415-22. (Pubitemid 32105982)
83. Jo S, Hu X, Kobayashi H, et al. Detection of inflammation following renal ischemia by magnetic resonance imaging. Kidney Int 2003;64:43-51, doi:10.1046/j.1523-1755.2003.00048.x. (Pubitemid 36714156)
84. Wiart M, Davoust N, Pialat JB, et al. MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke 2007;38:131-7, doi:10.1161/01. STR.0000252159.05702.00. (Pubitemid 46035618)
85. Denis MC, Mahmood U, Benoist C, et al. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A 2004;101:12634-9, doi:10.1073/pnas.0404307101. (Pubitemid 39122075)
86. Hauger O, Grenier N, Deminère C, et al. USPIO-enhanced MR imaging of macrophage infiltration in native and transplanted kidneys: initial results in humans. Eur Radiol 2007;17:2898-907, doi:10.1007/s00330-007-0660-8. (Pubitemid 47603986)
87. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003;107:2453-8, doi:10.1161/01. CIR.0000068315.98705. CC. (Pubitemid 36605228)
88. Dousset V, Brochet B, Deloire MS, et al. MR imaging of relapsing multiple sclerosis patients using ultra-small-particle iron oxide and compared with gadolinium. AJNR Am J Neuroradiol 2006;27:1000-5. (Pubitemid 44897675)
89. McAteer MA, Sibson NR, von Zur Muhlen C, et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med 2007;13:1253-8, doi:10.1038/nm1631. (Pubitemid 47530626)
90. McAteer MA, Schneider JE, Ali ZA, et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler Thromb Vasc Biol 2008;28:77-83, doi:10.1161/ATVBAHA.107.145466.
91. Akhtar AM, Schneider JE, Chapman SJ, et al. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One 2010;5:e12800, doi:10.1371/journal. pone.0012800.
92. Hoyte LC, Brooks KJ, Nagel S, et al. Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab 2010;30:1178-87, doi:10.1038/jcbfm.2009.287.
93. von Zur Muhlen C, von Elverfeldt D, Choudhury RP, et al. Functionalized magnetic resonance contrast agent selectively binds to glycoprotein IIb/IIIa on activated human platelets under flow conditions and is detectable at clinically relevant field strengths. Mol Imaging 2008;7:59-67.
94. von zur Muhlen C, Peter K, Ali ZA, et al. Visualization of activated platelets by targeted magnetic resonance imaging utilizing conformation-specific antibodies against glycoprotein IIb/IIIa. J Vasc Res 2009;46:6-14, doi:10.1159/000135660.
95. von zur Muhlen C, von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 2008;118:258-67, doi:10.1161/CIRCULATIONAHA.107.753657.
96. Duerschmied D, Meissner M, Peter K, et al. Molecular magnetic resonance imaging allows the detection of activated platelets in a new mouse model of coronary artery thrombosis. Invest Radiol 2011;46:618-23, doi:10.1097/RLI. 06013e31821e62f6.
97. von Zur Muhlen C, Sibson NR, Peter K, et al. A contrast agent recognizing activated platelets reveals murine cerebral malaria pathology undetectable by conventional MRI. J Clin Invest 2008;118:1198-207. (Pubitemid 351364626)
98. Morishige K, Kacher DF, Libby P, et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 2010;122:1707-15, doi:10.1161/CIRCULATIONAHA.109.891804.
99. Turvey SE, Swart E, Denis MC, et al. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest 2005;115:2454-61, doi:10.1172/JCI25048. (Pubitemid 41266207)
100. Sipkins DA, Gijbels K, Tropper FD, et al. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J Neuroimmunol 2000;104:1-9, doi:10.1016/S0165-5728 (99) 00248-9. (Pubitemid 30100884)
101. Barber PA, Foniok T, Kirk D, et al. MR molecular imaging of early endothelial activation in focal ischemia. Ann Neurol 2004;56:116-20, doi:10.1002/ana.20162. (Pubitemid 38857366)
102. Jin AY, Tuor UI, Rushforth D, et al. Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci 2010;11:12, doi:10.1186/1471-2202-11-12.
103. Sibson NR, Blamire AM, Bernades-Silva M, et al. MRI detection of early endothelial activation in brain inflammation. Magn Reson Med 2004;51:248-52, doi:10.1002/mrm.10723. (Pubitemid 38168583)
104. Van Kasteren SI, Campbell SJ, Serres S, et al. Glyconanoparticles allow pre-symptomatic in vivo imaging of brain disease. Proc Natl Acad Sci U S A 2009;106:18-23, doi:10.1073/pnas.0806787106.
105. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006;114:1504-11, doi:10.1161/CIRCULATIONAHA.106. 646380. (Pubitemid 44527006)
106. Choi KS, Kim SH, Cai QY, et al. Inflammation-specific T1 imaging using anti-intercellular adhesion molecule 1 antibodyconjugated gadolinium diethylenetriaminepentaacetic acid. Mol Imaging 2007;6:75-84.
107. Long CM, van Laarhoven HW, Bulte JW, et al. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res 2009;69:3180-7, doi:10.1158/0008-5472. CAN-08-3691.
108. Hultman KL, Raffo AJ, Grzenda AL, et al. Magnetic resonance imaging of major histocompatibility class II expression in the renal medulla using immunotargeted superparamagnetic iron oxide nanoparticles. ACS Nano 2008;2:477-84, doi:10.1021/nn700400h.
109. Flogel U, Ding Z, Hardung H, et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation 2008;118:140-8, doi:10.1161/CIRCULATIONAHA.107.737890.
110. Hertlein T, Sturm V, Kircher S, et al. Visualization of abscess formation in a murine thigh infection model of Staphylococcus aureus by F-magnetic resonance imaging (MRI). PLoS One 2011;6:e18246, doi:10.1371/journal.pone. 0018246.
111. Weissleder R, Kelly K, Sun EY, et al. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 2005;23:1418-23, doi:10.1038/nbt1159. (Pubitemid 41679395)
112. Moriyama EH, Zheng G, Wilson BC. Optical molecular imaging: from single cell to patient. Clin Pharmacol Ther 2008;84:267-71, doi:10.1038/clpt.2008.58.
113. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature 2008;452:580-9, doi:10.1038/nature06917. (Pubitemid 351483372)
114. Chen J, Tung CH, Mahmood U, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation 2002;105:2766-71, doi:10.1161/01. CIR.0000017860.20619.23. (Pubitemid 34615149)
115. Ntziachristos V, Ripoll J, Wang LV, et al. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol 2005;23:313-20, doi:10.1038/nbt1074. (Pubitemid 41094419)
116. Graves EE, Ripoll J, Weissleder R, et al. A submillimeter resolution fluorescence molecular imaging system for small animal imaging. Med Phys 2003;30:901-11, doi:10.1118/1.1568977. (Pubitemid 36578694)
117. Zacharakis G, Ripoll J, Weissleder R, et al. Fluorescent protein tomography scanner for small animal imaging. IEEE Trans Med Imaging 2005;24:878-85, doi:10.1109/TMI.2004.843254. (Pubitemid 41118465)
118. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005;308:1314-8, doi:10.1126/science.1110647. (Pubitemid 40746128)
119. Meier R, Krug C, Golovko D, et al. Indocyanine green-enhanced imaging of antigen-induced arthritis with an integrated optical imaging/radiography system. Arthritis Rheum 2010;62:2322-7, doi:10.1002/art.27542.
120. Simon GH, Daldrup-Link HE, Kau J, et al. Optical imaging of experimental arthritis using allogeneic leukocytes labeled with a near-infrared fluorescent probe. Eur J Nucl Med Mol Imaging 2006;33:998-1006, doi:10.1007/s00259-006-0081- y. (Pubitemid 44215665)
121. Streeter PR, Rouse BT, Butcher EC. Immunohistologic and functional characterization of a vascular addressin involved in lymphocyte homing into peripheral lymph nodes. J Cell Biol 1988;107:1853-62, doi:10.1083/jcb.107.5. 1853.
122. Licha K, Debus N, Emig-Vollmer S, et al. Optical molecular imaging of lymph nodes using a targeted vascular contrast agent. J Biomed Opt 2005;10:41205, doi:10.1117/1.2007967. (Pubitemid 43328897)
123. Baudy AR, Sali A, Jordan S, et al. Non-invasive optical imaging of muscle pathology in mdx mice using cathepsin caged nearinfrared imaging. Mol Imaging Biol 2010;13:462-70, doi:10.1007/s11307-010-0376-z.
124. Kar NC, Pearson CM. Muscular dystrophy and activation of proteinases. Muscle Nerve 1978;1:308-13, doi:10.1002/mus. 880010407. (Pubitemid 9023929)
125. Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8:752-8, doi:10.1038/nn1472. (Pubitemid 43085841)
126. White AG, Fu N, Leevy WM, et al. Optical imaging of bacterial infection in living mice using deep-red fluorescent squaraine rotaxane probes. Bioconjug Chem 2010;21:1297-304, doi:10.1021/bc1000998.
127. Eisenblatter M, Ehrchen J, Varga G, et al. In vivo optical imaging of cellular inflammatory response in granuloma formation using fluorescence-labeled macrophages. J Nucl Med 2009;50:1676-82, doi:10.2967/jnumed.108.060707.
128. Ntziachristos V. Optical imaging of molecular signatures in pulmonary inflammation. Proc Am Thorac Soc 2009;6:416-8, doi:10.1513/pats.200901-003AW.
129. Song H, He C, Knaak C, et al. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 2003;111:1875-85. (Pubitemid 38057732)